Abstract:Schistosomiasis-associated Pulmonary Arterial Hypertension (Sch-PAH) is a life-threatening complication of chronic S. mansoni infection that can lead to heart failure and death. During PAH, the expansion of apoptosis-resistant endothelial cells (ECs) has been extensively reported; however, therapeutic approaches to prevent the progression or reversal of this pathological phenotype remain clinically challenging. Previously, we showed that depletion of the anti-apoptotic protein Caveolin-1 (Cav-1) by shedding extracellular vesicles contributes to shifting endoprotective bone morphogenetic protein receptor 2 (BMPR2) towards transforming growth factor beta (TGF-β)-mediated survival of an abnormal EC phenotype. However, the mechanism underlying the reduced endoprotection in PAH remains unclear. Interestingly, recent findings indicate that, similar to the gut, healthy human lungs are populated by diverse microbiota, and their composition depends significantly on intrinsic and extrinsic host factors, including infection. Despite the current knowledge that the disruption of the gut microbiome contributes to the development of PAH, the role of the lung microbiome remains unclear. Thus, using a preclinical animal model of Sch-PAH, we tested whether S. mansoni infection alters the gut-lung microbiome composition and causes EC injury, initiating the expansion of an abnormal EC phenotype observed in PAH. Indeed, in vivo stimulation with S. mansoni eggs significantly altered the gut-lung microbiome profile, in addition to promoting injury to the lung vasculature, characterized by increased apoptotic markers and loss of endoprotective expression of lung Cav-1 and BMPR2. Moreover, S. mansoni egg stimulus induced severe pulmonary vascular remodeling, leading to elevated right ventricular systolic pressure and hypertrophy, characteristic of PAH. In vitro, exposure to the immunodominant S. mansoni egg antigen p40 activated TLR4/CD14-mediated transient phosphorylation of Cav-1 at Tyr14 in human lung microvascular EC (HMVEC-L), culminating in a mild reduction of Cav-1 expression, but failed to promote death and shedding of extracellular vesicles observed in vivo. Altogether, these data suggest that disruption of the host-associated gut-lung microbiota may be essential for the emergence and expansion of the abnormal lung endothelial phenotype observed in PAH, in addition to S. mansoni eggs and antigens.

Schistosomiasis-associated pulmonary hypertension unveils disrupted murine gut-lung microbiome and reduced endoprotective Caveolin-1/BMPR2 expression

S34 Bmpr-ii Deficiency Leads to an Increase in Lung Egg Deposition, Pulmonary Vascular Remodelling and an Abnormal Liver Vasculature in Mice Chronically Infected with S. Mansoni

Bmpr-Ii Deficiency Leads to an Increase in Egg Deposition and Cytokine Release in the Lungs of Mice Chronically Infected with Schistosomiasis

Abstract 14566: the Role of Eosinophils in Pulmonary Hypertension

MSC Transplantation Attenuates Inflammation, Prevents Endothelial Damage and Enhances the Angiogenic Potency of Endogenous MSCs in a Model of Pulmonary Arterial Hypertension

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension

Pulmonary arterial hypertension-associated changes in gut pathology and microbiota

Experimental Schistosoma haematobium pulmonary hypertension

Interstitial macrophage phenotypes in Schistosoma-induced pulmonary hypertension

Microbiome and metabolome dysbiosis of the gut-lung axis in pulmonary hypertension

Intrapulmonary T Cells Are Sufficient for Schistosoma-Induced Pulmonary Hypertension

Effects of the ACE2-Ang-(1-7)-Mas axis on gut flora diversity and intestinal metabolites in SuHx mice

Altered purinergic P2X7 and A 2B receptors signaling limits macrophage-mediated host defense in schistosomiasis

Gut Pathology and Its Rescue by ACE2 (Angiotensin-Converting Enzyme 2) in Hypoxia-Induced Pulmonary Hypertension

Critical Role of Caveolin-1 Loss/Dysfunction in Pulmonary Hypertension

Abstract 14257: Endothelial SOX17 Deficiency Induces Pulmonary Arterial Hypertension

Abstract 658: Endothelial And Smooth Muscle Cell Interaction In The Maintenance Of Pathological Muscularization In Pulmonary Hypertension

Changes in the gut microbiome and metabolome in a rat model of pulmonary arterial hypertension

Disease-associated gut microbiome and metabolome changes in rats with chronic hypoxia-induced pulmonary hypertension

Caveolin-1 expression during the progression of pulmonary hypertension

Role of Gut Microbiota in Pulmonary Arterial Hypertension